Skip to main content
. 2024 Feb 19;11:1366769. doi: 10.3389/fmed.2024.1366769

Table 8.

Clinicopathological features of RECQL VUSs and non-mutated patients.

VUS Nonmutated p
Age 0.374
≤40 11 (22.00%) 386 (18.66%)
>40 39 (78.00%) 1,683 (81.34%)
Histopathological types <0.001
Invasive ductal carcinoma 44 (91.67%) 1,676 (97.10%)
Carcinoma in situ 2 (4.17%) 44 (2.55%)
Other types 2 (4.17%) 6 (0.35%)
Molecular subtyping 0.037
Luminal A 5 (10.42%) 155 (9.04%)
Luminal B 24 (50.00%) 1,125 (65.64%)
TNBC 2 (4.17%) 106 (6.18%)
HER2+ 17 (35.42%) 328 (19.14%)
Histologic staging 0.870
I 9 (19.15%) 334 (18.64%)
II 27 (57.45%) 960 (53.57%)
III 9 (19.15%) 434 (24.2%)
unknown 2 (4.26%) 64 (3.57%)
TNM
0 2 (4.00%) 205 (10.07%) 0.083
I 10 (20.00%) 566 (27.80%)
II 21 (42.00%) 844 (41.45%)
III 10 (20.00%) 250 (12.28%)
IV 5 (10.00%) 69 (3.39%)
unknown 2 (4.00%) 102 (5.01%)
Tumor size 0.983
≤2 cm 26 (60.47%) 1,030 (60.30%)
>2 cm 17 (39.53%) 678 (39.70%)
Lymphonodus 0.520
Positive 36 (78.26%) 1,490 (81.24%)
Negative 10 (21.74%) 328 (17.88%)
Unknown 0 16 (0.87%)
Family history of breast tumors 0.002
Yes 19 (38.00%) 420 (20.27%)
No 31 (62.00%) 1,652 (79.73%)
Family history of other tumors 0.034
Yes 26 (52.00%) 773 (37.31%)
No 24 (48.00%) 1,299 (62.69%)
Distant metastasis 0.838
Yes 3 (6.00%) 159 (7.64%)
No 47 (94.00%) 1922 (92.36%)